新的卵巢癌标志物COX-1的临床评价

CLINICAL SIGNIFICANCE OF A NEW MARKER COX-1 IN OVARIAN CANCER

本文探讨环氧化酶 (COX 1)作为卵巢癌标志物的临床意义。共收集经病理确诊的卵巢良恶性肿瘤资料 97例 ,应用双夹心酶联免疫吸附实验的原理 ,测定各组标本的血清COX 1含量 ,并同时测定CA12 5。卵巢癌病例组的COX 1阳性率为 5 2 78% ,明显高于对照组 (P <0 0 1) ,与CA12 5联合检测的阳性率达 86 89%。研究显示 ,COX 1在诊断和监测卵巢癌患者中有一定价值 ,可作为卵巢癌联合检测的一项新指标。

Clinical significance of ovarian cancer marker COX 1 was studied . The data were colected from 97 cases of ovarian benign and malignant orarian tumors diagnosed by pathology . A sandwich enzyme immunoassay procedure was designed for quantitative determinations of COX 1, and CA125 was detected. 52 78% of COX 1 was found to be positive in ovarian cancer group ( P <0 01), 86 89% of it was found to be positive when both COX 1 and CA125 were tested by conbination . Conclusion : COX 1 is a useful index for the in diagnosis and monitoring of ovarian cancer is of the important clinical significance.